Nuklearmedizin 2021; 60(04): 299-301
DOI: 10.1055/a-1345-3150
Case Report

Longterm Survial after Re-challenge with Radiumdichlorid – a Case Report

Bilêl Habacha
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn, Germany
,
Xiao Wei
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn, Germany
,
Florian C. Gärtner
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn, Germany
,
Jörg Ellinger
2   Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn, Bonn, Germany
,
Ralph A. Bundschuh
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn, Germany
,
Markus Essler
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Bonn, Germany
› Author Affiliations

Introduction

The life-prolonging effects of Radium-223-dichlorid (223RaCl2) have been shown in the ALSYMCA trial in 2013 [1] in patients with advanced prostate cancer and dominating bone metastases. Consequently, it was approved by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). Typical initial treatment consists of 6 cycles 223RaCl2 given in intervals of 4 weeks.

As often relapse of the disease can be observed in the treated patients after some time, soon the repeated application of 223RaCl2 was discussed and analyzed in prospective trials [2]. While toxicity of repeated application of 223RaCl2 was found to be acceptable and no major issue in most cases, the outcome was shown to be very variable. Therefore, we want to report on one patient in whom bone metastases of an advanced, castration-resistant prostate carcinoma could be stabilized for nearly two years with repeated treatment with 223RaCl2.



Publication History

Article published online:
18 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Parker C, Nilsson S, Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223
  • 2 Sartor O, Heinrich D, Mariados N. et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol 2017; 28: 2464-2471